Core Viewpoint - The report highlights the growth and trends in China's pharmaceutical manufacturing outsourcing (CMO/CDMO) industry, indicating a positive trajectory in export values and market development from 2026 to 2032 [1] Industry Summary - In November 2025, the total export value of China's pharmaceutical manufacturing industry reached 18.97 billion, marking a year-on-year increase of 1.6% [1] - From January to November 2025, the cumulative export value of the pharmaceutical manufacturing industry was 214.06 billion, with a year-on-year growth of 11.7% [1] - The report includes a statistical chart of the export value of the pharmaceutical manufacturing industry from 2019 to November 2025, showcasing the growth trend over the years [1] Company Summary - Listed companies mentioned include: Guoyao Modern (600420), Kunming Pharmaceutical Group (600422), Pian Zai Huang (600436), Qianjin Pharmaceutical (600479), Tianyao Pharmaceutical (600488), Guoyao Shares (600511), Lianhuan Pharmaceutical (600513), Hefei China (603122), Kanghui Pharmaceutical (603139), Shapuaisi (603168), Aoxiang Pharmaceutical (603229), and Daclin (603233) [1] - The report is published by Zhiyan Consulting, a leading industry consulting firm in China, specializing in in-depth industry research and providing comprehensive solutions for investment decisions [1]
2025年1-11月全国医药制造业出口货值为2140.6亿元，累计增长11.7%
Chan Ye Xin Xi Wang·2026-01-02 06:33